PMID- 32088177
OWN - NLM
STAT- MEDLINE
DCOM- 20201201
LR  - 20220405
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 874
DP  - 2020 May 5
TI  - Bisdemethoxycurcumin attenuates cisplatin-induced renal injury through 
      anti-apoptosis, anti-oxidant and anti-inflammatory.
PG  - 173026
LID - S0014-2999(20)30118-7 [pii]
LID - 10.1016/j.ejphar.2020.173026 [doi]
AB  - Cisplatin is a widely used chemotherapy drug that is first-line therapy for a 
      variety of tumors. Unfortunately, its adverse effects on various normal tissues 
      and organs, especially nephrotoxicity, threaten the life of patients. Although 
      the mechanism of cisplatin nephrotoxicity has been confirmed to be related to 
      oxidative stress, apoptosis of renal tubular epithelial cells and inflammatory 
      response, there is no effective prevention strategy in the clinic. Here, we found 
      that bisdemethoxycurcumin (BDMC), a natural compound, can significantly 
      attenuates cisplatin-induced apoptosis of renal tubular epithelial cells in vitro 
      at the concentration of 5-20 muM and has a significant protective effect on 
      cisplatin-induced kidney injury in mice at the dose of 50 mg/kg. Mechanistically, 
      BDMC attenuates cisplatin-induced apoptosis of renal tubular epithelial cells by 
      inhibiting cisplatin-induced up-regulation of p53. Meanwhile, BDMC counteracts 
      oxidative stress by inhibiting cisplatin-induced down-regulation of nuclear 
      factor erythroid-2-related factor 2 (Nrf2). BDMC also significantly reduced the 
      expression of intercellular adhesion molecule-1 (ICAM-1) and monocyte 
      chemoattractant protein-1 (MCP-1) proteins, as well as the expression and 
      translocation of the p65 subunit of nuclear factor-kappaB (NF-kappaB p65) into the 
      nucleus, all of which were increased in the kidney by cisplatin treatment. 
      Collectively, BDMC might be an effective prevention strategy which could against 
      cisplatin-induced nephrotoxicity, and our research may shed a new light on 
      treatment of drug toxicity.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Jin, Fuquan
AU  - Jin F
AD  - Center for Drug Safety Evaluation and Research of Zhejiang University, College of 
      Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
FAU - Chen, Xueqin
AU  - Chen X
AD  - Department of Oncology, Key Laboratory of Clinical Cancer Pharmacology and 
      Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's 
      Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, China.
FAU - Yan, Hao
AU  - Yan H
AD  - Center for Drug Safety Evaluation and Research of Zhejiang University, College of 
      Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
FAU - Xu, Zhifei
AU  - Xu Z
AD  - Center for Drug Safety Evaluation and Research of Zhejiang University, College of 
      Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
FAU - Yang, Bo
AU  - Yang B
AD  - Institute of Pharmacology & Toxicology, College of Pharmaceutical Sciences, 
      Zhejiang University, Hangzhou, 310058, China.
FAU - Luo, Peihua
AU  - Luo P
AD  - Center for Drug Safety Evaluation and Research of Zhejiang University, College of 
      Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China. Electronic 
      address: peihualuo@zju.edu.cn.
FAU - He, Qiaojun
AU  - He Q
AD  - Center for Drug Safety Evaluation and Research of Zhejiang University, College of 
      Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China. Electronic 
      address: qiaojunhe@zju.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20200220
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Antioxidants)
RN  - 0 (Ccl2 protein, mouse)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Diarylheptanoids)
RN  - 0 (Icam1 protein, mouse)
RN  - 0 (NF-E2-Related Factor 2)
RN  - 0 (Nfe2l2 protein, mouse)
RN  - 0 (Transcription Factor RelA)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 126547-89-5 (Intercellular Adhesion Molecule-1)
RN  - 2EFO1BP34R (bisdemethoxycurcumin)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/pharmacology/*therapeutic use
MH  - *Antineoplastic Agents
MH  - Antioxidants/pharmacology/*therapeutic use
MH  - Apoptosis/drug effects
MH  - Cell Line
MH  - Chemokine CCL2/metabolism
MH  - *Cisplatin
MH  - Diarylheptanoids/pharmacology/*therapeutic use
MH  - Humans
MH  - Intercellular Adhesion Molecule-1/metabolism
MH  - Kidney/drug effects/metabolism/pathology
MH  - Kidney Diseases/chemically induced/*drug therapy/metabolism/pathology
MH  - Male
MH  - Mice, Inbred ICR
MH  - NF-E2-Related Factor 2/metabolism
MH  - Oxidative Stress/drug effects
MH  - Transcription Factor RelA/metabolism
MH  - Tumor Suppressor Protein p53/metabolism
OTO - NOTNLM
OT  - Anti-apoptosis
OT  - Anti-inflammatory
OT  - Anti-oxidant
OT  - Bisdemethoxycurcumin
OT  - Cisplatin
OT  - Nephrotoxicity
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/02/24 06:00
MHDA- 2020/12/02 06:00
CRDT- 2020/02/24 06:00
PHST- 2019/09/15 00:00 [received]
PHST- 2020/02/04 00:00 [revised]
PHST- 2020/02/17 00:00 [accepted]
PHST- 2020/02/24 06:00 [pubmed]
PHST- 2020/12/02 06:00 [medline]
PHST- 2020/02/24 06:00 [entrez]
AID - S0014-2999(20)30118-7 [pii]
AID - 10.1016/j.ejphar.2020.173026 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2020 May 5;874:173026. doi: 10.1016/j.ejphar.2020.173026. Epub 
      2020 Feb 20.